Evidence map›Paper›PMID 37437386›Full record

ReviewBreast (Edinburgh, Scotland)2023

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers.

Melanie Machiels, Redouane Oulkadi, Trine Tramm, Shane R Stecklein, Navita Somaiah, Alex De Caluwé, Jonathan Klein, William T Tran, Roberto Salgado

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast (Edinburgh, Scotland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 6 countries.

Melanie MachielsDepartment of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium. Electronic address: Melanie.Machiels@gza.be.
Redouane OulkadiDepartment of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium.
Trine TrammDepartment of Pathology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Shane R SteckleinDepartments of Radiation Oncology, Pathology & Laboratory Medicine, And Cancer Biology, The University of Kansas Medical Center, KS, USA.
Navita SomaiahDivision of Radiotherapy and Imaging, The Institute of Cancer Research, Breast Unit, The Royal Marsden NHS Foundation Trust, UK.
Alex De CaluwéUniversité Libre de Bruxelles (ULB), Hôpitaux Universitaires de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium.
Jonathan KleinState University of New York (SUNY) Downstate Health Sciences University and Maimonides Medical Center, NY, United States.
William T TranDepartment of Radiation Oncology, University of Toronto & Sunnybrook Health Sciences Centre, Toronto, Canada.
Roberto SalgadoDivision of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA - ZNA Hospitals, Antwerp, Belgium.
Aarhus University Hospital · DKGZA Ziekenhuizen Campus Sint-Augustinus · BEHealth Sciences Centre · CAInstitute of Cancer Research · GBInstitut Jules Bordet · BEIridium Kankernetwerk · BEMaimonides Medical Center · USUniversity of Antwerp · BEUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.

Indexed as

Breast NeoplasmsBiomarkers, TumorFemaleGenomicsHumansLymphocytes, Tumor-InfiltratingPrognosisBiomarkers, TumorBiomarkersBreast cancerGene expression profileGenomically adjusted radiation dosePersonalised radiation therapyRadiation therapyResponse guided therapyTumour infiltrating lymphocytes

Identifiers

PMID37437386
PMCPMC10512095
OpenAlexW4382794593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.